Use access key #2 to skip to page content.
$9.18 -0.03 (-0.33%)
7/3/2008 12:59 PM

Repros Therapeutics, Inc. (RPRX)

CAPS Rating:
*

A biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating RPRX

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

33 Outperforms
15 Underperforms
 

All-Stars

6 Outperforms
13 Underperforms
 

Players bullish on RPRX are also bullish on:

Players bearish on RPRX are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (293)
Suggest a tag

Repros Therapeutics, Inc. At A Glance

Current Price: $9.18
Last Trade Time: 7/3/2008 12:59 PM
Open: $0.00
Previous Close: $9.21
Daily Range: $9.12 - $9.28
52-Week Range: $6.99 - $14.38
Volume: 25,500
Market Cap: $117.66M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

RPRX VS S&P 500 (SPY)

RPRX 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for RPRX.

Top Bull Pitch

Recs

1

Repros Therapeutics, Inc. (RPRX)

Avatar zzlangerhans (70.51) Submitted: 8/15/07 9:23 PM

Androxal and Proellex are likely 2008 NDA submissions. Coverage from unbiased sources is very thin, and there are potential problems with cytopathologic endometrial changes with Proellex. However, despite price near 13 market cap is only 165M which improves the risk/benefit profile substantially.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 9 :   1 2 Next »

Show Pitch Replies

Recs

0

 (RPRX)

Avatar EclecticRecluse (72.62) Submitted: 5/27/08 7:23 AM : Underperform Start Price: $9.16 RPRX Score: -8.56

Poor Forward Earnings Estimate

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (RPRX)

Avatar SanDieguito (97.42) Submitted: 12/03/07 3:08 PM : Underperform Start Price: $7.65 RPRX Score: -34.32

down $2 to $7

Report this Post Replies: 1 | Reply | Permalink

Recs

1

 (RPRX)

Avatar zzlangerhans (70.51) Submitted: 8/15/07 9:23 PM : Outperform Start Price: $12.68 RPRX Score: -17.96

Androxal and Proellex are likely 2008 NDA submissions. Coverage from unbiased sources is very thin, and there are potential problems with cytopathologic endometrial changes with Proellex. However, despite price near 13 market cap is only 165M which improves the risk/benefit profile substantially.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (RPRX)

Avatar ProphetOfProfits (87.16) Submitted: 7/27/07 10:59 AM : Outperform Start Price: $13.20 RPRX Score: -16.22

Good clinical data re Proellex safety is a good enough reason for me to hop in again

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (RPRX)

Avatar jbfoolsgold (< 20) Submitted: 7/17/07 10:47 PM : Outperform Start Price: $13.16 RPRX Score: -12.14

Strong development pipeline, product potentials and buyout potentials. It is just a matter of time before something happens to push to $20.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 9 :   1 2 Next »

Wall Street

There are no Wall Street player picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners